Login to Your Account



Clinic Roundup


Tuesday, January 17, 2012
If it can raise enough capital in the near term, Omni Bio Pharmaceutical Inc., of Denver, said it plans to begin two new clinical trials to test the efficacy of alpha-1 antitrypsin as a treatment for Type I diabetes and graft-vs.-host disease (GVHD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription